Previous 10 | Next 10 |
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Elif McDo...
MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting ...
Theratechnologies (NASDAQ:THTX) said it began enrollment of patients in the basket portion of a first-in-human study of TH1902 to treat sortilin-expressing cancers. The company said TH1902 is a proprietary peptide drug conjugate linked to docetaxel, a chemotherapy. "TH1902’s...
Phase 1b dose established at 300 mg/m 2 or 1.5 times the therapeutic dose of docetaxel alone Expansion study will evaluate TH1902 in solid tumors with high expression of Sortilin receptor MONTREAL, May 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies In...
THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY Canada NewsWire MONTREAL , April 27, 2022 /CNW Telbec/ - Theratechnologies Inc. (Theratechnologies or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical c...
MONTREAL, April 27, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( Theratechnologies or Company ) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will focus its commercializati...
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company&...
Theratechnologies Inc. (THTX) Q1 2022 Earnings Conference Call April 12, 2022 8:30 a.m. ET Company Participants Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer John Mullaly - IR, LifeSci Advisors Conference Call Particip...
The following slide deck was published by Theratechnologies Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Theratechnologies Inc. 2022 Q1 - Results - Earnings Call Presentation
Theratechnologies press release (NASDAQ:THTX): Q1 Net Loss of $9.03M Revenue of $18.56M (+20.3% Y/Y) misses by $3M. 2022 Revenue Guidance: The company affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022 vs consensus of $81.82M, or growth of ...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...